# US 2018/0021347 A1 · Composition for the treatment of hepatic veno-occlusive disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021347 A1
- Document ID: US20180021347A1
- Status: Published application
- Kind: A1
- Application number: 15/547,060
- Filed: 2016-01-27
- Published: 2018-01-25
- Earliest claimed: 2015-01-27
- Assignees: SciPharm SaRL
- Applicants: Scipharm SàRl
- Inventors: Michael Freissmuth; Eva-Maria Zebedin-Brandl; Zahra Kazemi; Christoph Österreicher; Ursula Lemberger; Madeleine Themanns
- Web page: https://patentgrep.com/patent/US20180021347A1

## CPC

- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/5578: having a pentalene ring system, e.g. carbacyclin, iloprost
- A61K 31/5585: having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a composition comprising a prostacyclin analogue, derivative or a pharmaceutically acceptable salt thereof, for use in preventing or treating the sinusoidal obstruction syndrome and/or hepatic veno-occlusive disease (VOD) as well as treatment regimens therefor.

## Claims

### Claim 1

A method of preventing or treating sinusoidal obstruction syndrome and/or hepatic veno-occlusive disease (VOD), comprising the step of administering to a subject in need thereof a composition comprising a prostacyclin analogue or a derivative or pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein said prostacyclin analogue is selected from the group consisting of treprostinil, iloprost, cicaprost, beraprost, and derivatives or pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein said derivative is selected from the group consisting of acid derivatives of treprostinil, prodrugs of treprostinil, sustained release forms of treprostinil, inhaled forms of Treprostinil, oral forms of treprostinil, polymorphs of treprostinil, and isomers of treprostinil.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition is administered systemically.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition is administered locally administration.

### Claim 6 (depends on 1)

The method of claim 1, wherein said composition is in an orally available form selected from the group consisting of tablets and capsules.

### Claim 7 (depends on 2)

The method of claim 2, wherein the treprostinil or its derivative or a pharmaceutically acceptable salt thereof is administered in an effective amount ranging between 0.1 ng/kg/min and 100 ng/kg/min.

### Claim 8 (depends on 2)

The method of claim 2, wherein treprostinil is administered to a patient at risk of or suffering from VOD at a dose to improve the patient's liver function and/or normalize coagulation time.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition is administered to a patient suffering from mild to moderate VOD.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is administered to a patient at risk of VOD following therapy with chemotherapeutic agents, irradiation, anti-CD33 targeting immunotoxins, or haematopoetic stem cell (HES) transplantation.

### Claim 11 (depends on 10)

The method of claim 10, wherein the patient is suffering from bone marrow disease.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is continuously treated with the composition for a period of between 1 month and 3 months.

### Claim 13 (depends on 12)

The method of claim 12, wherein the subject is treated with treprostinil at a daily dose of 0.1 to 10 mg.

### Claim 14

(canceled)

### Claim 15 (depends on 4)

The method of claim 4, wherein the composition is administered by intravenous or subcutaneous infusion.

### Claim 16 (depends on 5)

The method of claim 5, wherein the composition is administered by inhalation.

### Claim 17 (depends on 10)

The method of claim 10, wherein the patient is undergoing HES transplantation.

### Claim 18 (depends on 12)

The method of claim 12, wherein the subject is continuously treated with the composition for a period of at least 2 months.

### Claim 19 (depends on 13)

The method of claim 13, wherein the subject is treated by continuous subcutaneous infusion.
